Despite several multi-tyrosine kinase and BRAF-specific inhibitors being FDA and EMA approved for BRAF-mutant THCA tumours they are less sensitive to these drugs than melanoma, rapidly developing resistance, and new treatment strategies continue to be evaluated, including combination therapies (25). The gene discussed is BRAF; the disease is neoplasm.